GlobeNewswire

Inspirata Unveils Comprehensive Insight Solutions for the Cancer Care Continuum

Share

Leading digital pathology company now offers technology-enabled insight solutions

Tampa, Florida, June 18, 2019 (GLOBE NEWSWIRE) --

Cancer informatics and digital pathology solution provider Inspirata today unveiled its new end-to-end capabilities for the cancer care continuum. Founded as a digital pathology company that pioneered the use of digital imaging for accurate cancer diagnoses, Inspirata now offers cancer registry abstraction and insight solutions to drive better cancer diagnosis, treatment, performance, and research.

Inspirata’s comprehensive solutions reveal a clear picture of patients, allowing clinicians to make every moment matter in delivering cancer care. With an existing global footprint that serves over 100 institutions with automated cancer identification and reporting, and more than 30 hospitals and laboratories with digital pathology, Inspirata processes over 20 million patient reports per year, identifying all reports containing reportable cancer. Today, the company also offers cancer centers the world’s most advanced cancer informatics solution, enabling them to rapidly gain insights that can improve cancer outcomes and operations. Inspirata’s solutions integrate directly with most cancer centers’ EHRs and ancillary systems, abstract unstructured data, and use artificial intelligence (AI) and natural language processing (NLP) to convert data into meaningful insights. These are delivered directly into the clinician’s workflow through Inspirata’s Knowledge Hub auto-alert EHR overlay, or custom user interfaces.

“Inspirata’s solutions accurately identify eligible cancer pathology reports missed by previous notification methods with a high degree of sensitivity and specificity,” said Dr. Catherine Shang, Ph.D., Acting Director of the Victorian Cancer Registry in Melbourne Australia. “We now receive 60 percent more reportable pathology notifications than we did prior to implementation, including those for ancillary studies. This has greatly improved our case-finding completeness and contributed to more accurate and precise diagnosis and cancer classification.”

“Inspirata delivers practical interoperability that solves real-world clinical challenges,” said Sam Carello, Director of Biomedical Informatics at SUNY Upstate. “In our pathology department, we’re using Inspirata to automate the extraction of diagnostic data from our images and molecular datasets. Inspirata then integrates with our Laboratory Information System to efficiently deliver the data across the enterprise. Our consultation, education, clinical research and tumor boards now have access to meaningful insights that are helping them improve care for our patients.” 

“This industry holds such great opportunity to be innovative and disruptive,” said Satish Sanan, CEO of Inspirata. “Clinicians and researchers need more comprehensive, accurate and timely data to truly be able to put their patients first. No one’s health should suffer because key information is missing. This is what compelled me to envision an insights-driven cancer care journey that can truly deliver a clearer picture of the patient, enabling the best care options and driving better research. Inspirata is here to make sure that every moment matters for cancer centers and cancer patients.”


About Inspirata, Inc.
Inspirata®, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship. 

Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. For more information, please visit www.inspirata.com or contact info@inspirata.com.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders15.10.2019 17:50:00 CESTPress release

Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders Company announcement, inside information, Helsinki 15 October 2019 at 6.50 PM (EEST) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD), invites the shareholders to attend the Extraordinary General Meeting of Shareholders of the Company on 11 November 2019 commencing at 10.00 (EEST) at the auditorium of Hotel Haven, Unioninkatu 17 Helsinki, Finland. The reception of persons who have registered for the meeting will commence at 9.30. A. Matters on the agenda of the Extraordinary General Meeting of Shareholders At the Extraordinary General Meeting of Shareholders, the following matters will be considered: 1 OPENING OF THE MEETING 2 CALLING THE MEETING TO ORDER 3 ELECTION OF PERSONS TO SCRUTINIZE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES 4 RECORDING THE LEGALI

Nexstim Abp: Kallelse till extra bolagsstämma15.10.2019 17:50:00 CESTPressemelding

Nexstim Abp: Kallelse till extra bolagsstämma Pressmeddelande, insiderinformation, Helsingfors 15 oktober 2019, kl. 18.50 (EEST) Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”Bolaget”), ett företag som utvecklar och marknadsför en unik hjärnstimuleringsteknologi för personlig behandling av egentlig depression (eng. Major Depression Disorder), kallar härmed aktieägarna till extra bolagsstämma 11 november 2019, kl. 10.00 (EEST) i auditoriet på Hotel Haven, Unionsgatan 17 i Helsingfors, Finland. Mottagandet av personer som har registrerat sig för bolagsstämman inleds kl. 9.30. A. Ärenden på extrastämmans dagordning Vid extrastämman ska följande ärenden behandlas: 1 STÄMMANS ÖPPNANDE 2 STÄMMANS KONSTITUERING 3 VAL AV PROTOKOLLJUSTERARE OCH RÖSTRÄKNARE 4 FASTSTÄLLELSE AV ATT STÄMMAN BLIVIT BEHÖRIGEN SAMMANKALLAD 5 FASTSTÄLLANDE AV NÄRVAROLISTA OCH RÖSTLÄNGD 6 STYRELSEKOMMITTÉER OCH INRÄTTANDET AV VALBEREDNINGEN FÖR AKTIEÄGARNA Bolaget har haft två styrelsekommittéer: styrelsens revis

DNO ASA: Mandatory Notification of Trade15.10.2019 17:43:00 CESTPress release

Oslo, 15 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,100,000 own shares at an average price of NOK 12.6653 per share. Following this transaction, DNO holds 75,500,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Ress Life Investments A/S publishes Net Asset Value (NAV) per share.15.10.2019 17:20:00 CESTPress release

Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 15 October 2019 Corporate Announcement 34/2019 Ress Life Investments A/S publishes Net Asset Value (NAV) per share. Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 30 September 2019. NAV per share in USD: 1918.35 NAV per share in EUR: 1761.73 The performance during September 2019 was 0.97% in USD. The performance during the month was positively affected by one policy paying out and mark-to-market adjustments. The year-to-date net performance as of 30 September 2019 is 5.76% in USD. Assets under management (AUM) as of 30 September 2019 was 155.1 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount

GOGL – Repurchase of shares15.10.2019 16:44:00 CESTPress release

Golden Ocean Group Limited (“Golden Ocean” or the “Company”) announces that the Company has, on October 15, 2019 purchased 50,000 of the Company's own common stocks. The shares have been bought on the Oslo Stock Exchange at an average price of NOK 53.96 per share. After this transaction Golden Ocean holds a total of 1,250,000 own shares. The transaction is part of the share buyback program announced on December 20, 2018. Hamilton, Bermuda October 15, 2019 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Scanship Holding ASA : Scanship acquires ETIA - Transaction has been completed15.10.2019 16:16:00 CESTPress release

Reference is made to the notice to the stock exchange dated 28.08.19 regarding the acquisition of ETIA Ecotechnologies ("ETIA" or the "Company"). The transaction has now been completed. Scanship has as part of the closing issued 3 888 041 new shares in SSHIP to the sellers of ETIA. The new share capital of SSHIP is after the share issue NOK 10 006 356.60, and total number outstanding shares are 100 063 566. SSHIP has also issued convertible loans for EUR 4 179 000 in total, in respect of a 9 months' seller credit. The conversion may be elected by the sellers, and the conversion price will be NOK 19.33 per share. For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: henrik.badin@scanship.no ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advanced technologies for processing waste and purifying wastewater. Owners operating Scanship systems